The primary objective of the Biostatistics Core is to assist to the project investigators in the design, conduct, and analysis ofthe laboratory and clinical studies proposed in this program project grant (PPG). This core is led by Dr. Gary Rosner, Director of the Oncology Biostatistics and Bioinformatics Division. The Core focuses its efforts on assisting both the clinical and laboratory investigators in translating their pre-clinical studies into clinical studies by providing state-of-the-art experimental designs and analyses through statistical consultation and collaboration with respect to methodology, feasibility, safety monitoring, analysis, and reporting of clinical and laboratory studies. Additionally, Core members work closely with members of the Research Information Technology Systems (RITS) group, part of Oncology's Division of Biostatistics and Bioinformatics, to provide quality-controlled data in a systematic, efficient, and coordinated fashion so that accurate, complete, validated databases are available. This core has been and continues to be an integral part of the research accomplishments of the individual projects of this program project application

Public Health Relevance

The work ofthe Biostatistics Core helps ensure that laboratory and clinical studies are carried out efficiently with designs that will lead to valid scientific conclusions. This work is a critical part ofthe research seeking to improve outcomes for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-39
Application #
8727266
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
39
Fiscal Year
2014
Total Cost
$150,409
Indirect Cost
$57,564
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kanakry, Christopher G; O'Donnell, Paul V; Furlong, Terry et al. (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32:3497-505
Fuchs, Ephraim J (2014) Transplantation tolerance: from theory to clinic. Immunol Rev 258:64-79
Showel, Margaret M; Brodsky, Robert A; Tsai, Hua-Ling et al. (2014) Isolated clonal cytogenetic abnormalities after high-dose therapy. Biol Blood Marrow Transplant 20:1130-8
Fu, Juan; Malm, Ian-James; Kadayakkara, Deepak K et al. (2014) Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 74:4042-52
Goswami, M; Hensel, N; Smith, B D et al. (2014) Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 28:1167-70
Agarwal, Jasmin R; Wang, Qiuju; Tanno, Toshihiko et al. (2014) Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther 13:1873-81
Eapen, Mary; O'Donnell, Paul; Brunstein, Claudio G et al. (2014) Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant 20:1485-92
Zeidan, Amer M; Forde, Patrick M; Symons, Heather et al. (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314-8
Gerber, Jonathan M; Gucwa, Jessica L; Esopi, David et al. (2013) Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 4:715-28
Kanakry, Jennifer A; Kasamon, Yvette L; Bolanos-Meade, Javier et al. (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:1514-7

Showing the most recent 10 out of 393 publications